Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 14Neoplasm Metastasis 12Carcinoma, Medullary 12Neoplasms 10Thyroid Neoplasms 8Breast Neoplasms 8Glioma 6Prostatic Neoplasms 5Glioblastoma 5Squamous Cell Carcinoma of Head and Neck 4Gliosarcoma 4Colorectal Neoplasms 4Brain Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Thyroid Cancer, Papillary 2Stomach Neoplasms 2Recurrence 2Rectal Neoplasms 2Pleural Effusion 2Kidney Neoplasms 2Familial medullary thyroid carcinoma 2Fallopian Tube Neoplasms 2Esophageal Neoplasms 2Disease Progression 2

Interventions

Temozolomide 111Radiotherapy 60Carboplatin 30Bevacizumab 30Magnetic Resonance Spectroscopy 28Carmustine 28Filgrastim 23Surgical Procedures, Operative 22Irinotecan 22Radiation 17Lomustine 16Vincristine 15Etoposide 15Specimen Handling 13Peripheral Blood Stem Cell Transplantation 13O(6)-benzylguanine 13Radiotherapy, Intensity-Modulated 12Procarbazine 11Erlotinib Hydrochloride 11Cyclophosphamide 11Chemotherapy, Adjuvant 11sargramostim 10Thiotepa 10Cisplatin 10Flucytosine 9Everolimus 9antineoplaston AS 2-1 8antineoplaston A10 8Granulocyte Colony-Stimulating Factor 8Vorinostat 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Astrocytoma × vandetanib × Clear all
NCT00995007 2016-03-29

A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
112 enrolled 12 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡